Vadivarhe Speciality Chemicals Secures Purchase Orders from Leading Japanese Chemical Firm and Turkish Pharma Company
Vadivarhe Speciality Chemicals Limited has announced securing significant purchase orders from two international clients, one in Japan and another in Turkey. The orders cover the supply of Speciality Chemicals and Active Pharmaceuticals Ingredients, respectively.The company reported receiving purchase orders aggregating to Rs. 4,66,05,000 from a leading chemical company in Japan. Separately, Vadivarhe received an order valued at Rs. 5,84,42,670 from a leading pharmaceutical company based in Turkey.
The two international contracts detail specific product requirements and delivery timelines. The Japan-based order is for the supply of Speciality Chemicals and is structured in five tranches, with the last tranche PSS due before October 31, 2026. The corresponding cargo must be dispatched within 3 to 4 weeks after PSS approval.
For the Turkish contract, the supply of Active Pharmaceuticals Ingredients is scheduled for two lots, with deliveries required before August 3, 2026, and another lot before October 1, 2026.
The key details of the transactions are outlined below:
| Particulars | Japan Order Details | Turkey Order Details |
|---|---|---|
| Client Nature | Leading Chemical Company (International) | Leading Pharma company (International) |
| Product Type | Supply of Speciality Chemicals | Supply of Active Pharmaceuticals Ingredients |
| Order Value | Rs. 4,66,05,000 | Rs. 5,84,42,670 |
| Timeline | 5 tranches; Last PSS before Oct 31, 2026 | Two lots; Due before Aug 3, 2026, and Oct 1, 2026 |
| Promoter Interest | No | No |
VSCL Stock Price Movement
On Monday, Vadivarhe Speciality Chemicals Limited shares settled exactly at ₹25.50, maintaining a flat movement for the session. The equity recorded a total traded volume of 45,000 shares during the day's trading.Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.